The estimated Net Worth of Momoko A Beran is at least $13.3 Millón dollars as of 2 May 2011. Momoko Beran owns over 70,000 units of Simulations Plus stock worth over $13,300,551 and over the last 19 years Momoko sold SLP stock worth over $0.
Momoko has made over 2 trades of the Simulations Plus stock since 2011, according to the Form 4 filled with the SEC. Most recently Momoko exercised 70,000 units of SLP stock worth $24,500 on 2 May 2011.
The largest trade Momoko's ever made was exercising 70,000 units of Simulations Plus stock on 2 May 2011 worth over $24,500. On average, Momoko trades about 4,000 units every 2 days since 2005. As of 2 May 2011 Momoko still owns at least 405,381 units of Simulations Plus stock.
You can see the complete history of Momoko Beran stock trades at the bottom of the page.
Momoko's mailing address filed with the SEC is 1220 W AVENUE J, , LANCASTER, CA, 93534.
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz y Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: